Skip header and navigation

Refine By

11 records – page 1 of 2.

Access to care for rheumatology patients may be compromised: results of a survey to members of the Canadian Rheumatology Association.

https://arctichealth.org/en/permalink/ahliterature173517
Source
J Rheumatol. 2005 Aug;32(8):1418-21
Publication Type
Article
Date
Aug-2005

Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort.

https://arctichealth.org/en/permalink/ahliterature105048
Source
Rheumatology (Oxford). 2014 Jun;53(6):1075-86
Publication Type
Article
Date
Jun-2014
Author
Michael B Arnold
Vivian P Bykerk
Gilles Boire
Boulos P Haraoui
Carol Hitchon
Carter Thorne
Edward C Keystone
Janet E Pope
Source
Rheumatology (Oxford). 2014 Jun;53(6):1075-86
Date
Jun-2014
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Age Factors
Age of Onset
Aged
Aged, 80 and over
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - diagnosis - drug therapy - epidemiology
Biological Products - therapeutic use
Canada - epidemiology
Cohort Studies
Comorbidity
Drug Utilization - statistics & numerical data
Female
Humans
Male
Middle Aged
Prognosis
Remission Induction
Severity of Illness Index
Sex Factors
Treatment Outcome
Young Adult
Abstract
The aim of this study was to determine the impact of age on disease and remission in suspected early RA (ERA).
Data from the Canadian Early Arthritis Cohort (CATCH) were examined at baseline, 6 and 12 months. Patients were divided into three groups based on age. Analysis of variance (ANOVA) and regression models were performed to determine the impact of age on the 28-joint DAS (DAS28) and remission at 12 months.
A total of 1809 patients were initially assessed: 442 (24.4%) young (
PubMed ID
24501240 View in PubMed
Less detail

The Canadian Early Arthritis Cohort (CATCH): patients with new-onset synovitis meeting the 2010 ACR/EULAR classification criteria but not the 1987 ACR classification criteria present with less severe disease activity.

https://arctichealth.org/en/permalink/ahliterature121576
Source
J Rheumatol. 2012 Nov;39(11):2071-80
Publication Type
Article
Date
Nov-2012
Author
Vivian P Bykerk
Shahin Jamal
Gilles Boire
Carol A Hitchon
Boulos Haraoui
Janet E Pope
J Carter Thorne
Ye Sun
Edward C Keystone
Author Affiliation
Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. vbykerk@gmail.com
Source
J Rheumatol. 2012 Nov;39(11):2071-80
Date
Nov-2012
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antirheumatic Agents - therapeutic use
Canada
Cohort Studies
Europe
Female
Finger Joint - radiography
Humans
Male
Methotrexate - therapeutic use
Middle Aged
Patient Selection
Prospective Studies
Rheumatoid Factor - blood
Severity of Illness Index
Societies, Medical
Synovitis - classification - diagnosis - drug therapy
United States
Abstract
Our objective was to describe characteristics of Canadian patients with early arthritis and examine differences between those fulfilling 1987 and 2010 rheumatoid arthritis (RA) classification criteria.
The Canadian Early Arthritis Cohort (CATCH) is a national, multicenter, observational, prospective cohort of patients with early inflammatory arthritis, receiving usual care, recruited since 2007. Inclusion criteria include age > 16 years; symptom duration 6-52 weeks; swelling of = 2 joints or = 1 metacarpophalangeal/proximal interphalangeal joint; and 1 of rheumatoid factor = 20 IU, positive anticitrullinated protein antibodies (ACPA), morning stiffness = 45 min, response to nonsteroidal antiinflammatory drug, or positive metatarsophalangeal joint squeeze test. Data from patients enrolled to March 15, 2011, were analyzed.
In total, 1450 patients met the eligibility criteria (1187 were followed). At baseline, mean age was 53 ± 15 years, symptom duration was 6.1 ± 3.2 months, Disease Activity Score (DAS28) was 4.9 ± 1.6, Health Assessment Questionnaire-Disability Index was 1.0 ± 0.7. Forty-one percent (n = 450) of patients had moderate (3.2 5.1) disease activity; 28% of those with baseline radiographs (n = 250/908) had radiographic evidence of erosions. ACPA status was available for 70% (n = 831) of patients; 55% (n = 453) tested positive. Sixty percent (n = 718) of patients were treated with methotrexate (MTX) initially. Of 612 patients without erosions, 63% and 83% fulfilled 1987 and 2010 RA classification criteria, respectively. Seventy-three percent (n = 166) of those who did not fulfill 1987 criteria were newly identified by the 2010 criteria. These patients had less severe disease and more were MTX-naive compared to those satisfying the 1987 criteria. Forty-seven percent of all patients achieved remission at 1 year.
Patients with early RA present with moderate high disease activity;
Notes
Comment In: J Rheumatol. 2012 Nov;39(11):2062-323118277
PubMed ID
22896026 View in PubMed
Less detail

Canadian recommendations for clinical trials of pharmacologic interventions in rheumatoid arthritis: inclusion criteria and study design.

https://arctichealth.org/en/permalink/ahliterature132908
Source
J Rheumatol. 2011 Oct;38(10):2095-104
Publication Type
Article
Date
Oct-2011
Author
Jacob Karsh
Edward C Keystone
Boulos Haraoui
J Carter Thorne
Janet E Pope
Vivian P Bykerk
Walter P Maksymowych
Michel Zummer
William G Bensen
Majed M Kraishi
Author Affiliation
The Ottawa Hospital, Riverside Campus, 1967 Riverside Drive, Ottawa, ON K1H 7W9, Canada. jkarsh@ottawahospital.on.ca
Source
J Rheumatol. 2011 Oct;38(10):2095-104
Date
Oct-2011
Language
English
Publication Type
Article
Keywords
Arthritis, Rheumatoid - drug therapy
Canada
Clinical Trials as Topic
Humans
Patient Selection
Research Design
Abstract
Current clinical trial designs for pharmacologic interventions in rheumatoid arthritis (RA) do not reflect the innovations in RA diagnosis, treatment, and care in countries where new drugs are most often used. The objective of this project was to recommend revised entry criteria and other study design features for RA clinical trials.
Recommendations were developed using a modified nominal group consensus method. Canadian Rheumatology Research Consortium (CRRC) members were polled to rank the greatest challenges to clinical trial recruitment in their practices. Initial recommendations were developed by an expert panel of rheumatology trialists and other experts. A scoping study methodology was then used to examine the evidence available to support or refute each initial recommendation. The potential influence of CRRC recommendations on primary outcomes in future trials was examined. Recommendations were finalized using a consensus process.
Recommendations for clinical trial inclusion criteria addressed measures of disease activity [Disease Activity Score 28 using erythrocyte sedimentation rate (DAS28-ESR) > 3.2 PLUS = 3 tender joints using 28-joint count (TJC28) PLUS = 3 swollen joint (SJC28) OR C-reactive protein (CRP) or ESR > upper limit of normal PLUS = 3 TJC28 PLUS = 3 SJC28], functional classification, disease classification and duration, and concomitant RA treatments. Additional recommendations regarding study design addressed rescue strategies and longterm extension.
There is an urgent need to modify clinical trial inclusion criteria and other study design features to better reflect the current characteristics of people living with RA in the countries where the new drugs will be used.
Notes
Comment In: J Rheumatol. 2011 Oct;38(10):2087-821965690
PubMed ID
21765109 View in PubMed
Less detail

Care gap in patients with early inflammatory arthritis with a high fracture risk identified using FRAX(®).

https://arctichealth.org/en/permalink/ahliterature141497
Source
J Rheumatol. 2010 Nov;37(11):2221-5
Publication Type
Article
Date
Nov-2010
Author
Carly K Cheng
Heather McDonald-Blumer
Gilles Boire
Janet E Pope
Boulos Haraoui
Carol A Hitchon
Carter Thorne
Ye Sun
Vivian P Bykerk
Author Affiliation
Division of Rheumatology, Mount Sinai Hospital, 60 Murray Street, 2nd floor, Toronto, Ontario M5T 3L9, Canada.
Source
J Rheumatol. 2010 Nov;37(11):2221-5
Date
Nov-2010
Language
English
Publication Type
Article
Keywords
Adult
Aged
Analysis of Variance
Arthritis - complications
Body Weight
Bone Density
Canada
Chi-Square Distribution
Female
Humans
Male
Middle Aged
Osteoporosis - complications
Osteoporotic Fractures - etiology
Questionnaires
Risk assessment
Risk factors
Severity of Illness Index
Abstract
To determine the proportion of patients with early inflammatory arthritis in a Canadian cohort who are at high risk for a major osteoporotic fracture using the Fracture Risk Assessment Tool (FRAX(®)), and to determine if a care gap exists in high-risk patients.
FRAX was applied to 238 patients enrolled in the Canadian Early Arthritis Cohort (CATCH) study based on norms from the United States and the United Kingdom, without the use of bone mineral density measurements.
FRAX identified 5%-13% of patients at high risk for fracture, using a conservative analysis. Based on US norms, there was a significant correlation between increasing fracture risk groups and oral glucocorticoid use (p = 0.012) and baseline erosions (p = 0.040). Calcium or vitamin D use did not vary among the different fracture risk groups (p = NS), nor did bisphosphonate use (p = NS). The Disease Activity Score with 28 joint count in the high-risk group was significantly higher compared to the low-risk group (p = 0.048).
Patients at increased risk had higher disease activity, more frequent glucocorticoid use, and more baseline erosions compared to patients at low risk. A care gap exists, in that a very low proportion of patients at high risk are being treated with calcium, vitamin D, and/or bisphosphonates. A higher fracture risk was calculated in our cohort using the US FRAX calculation tool compared to the UK calculation tool. These data highlight the need to identify and modify fracture risk in patients with early inflammatory arthritis.
PubMed ID
20716658 View in PubMed
Less detail

Determining best practices in early rheumatoid arthritis by comparing differences in treatment at sites in the Canadian Early Arthritis Cohort.

https://arctichealth.org/en/permalink/ahliterature107248
Source
J Rheumatol. 2013 Nov;40(11):1823-30
Publication Type
Article
Date
Nov-2013
Author
Jamie A Harris
Vivian P Bykerk
Carol A Hitchon
E C Keystone
J Carter Thorne
Gilles Boire
Boulos Haraoui
Glen Hazlewood
Ashley J Bonner
Janet E Pope
Author Affiliation
From the Rheumatology Centre, St. Joseph's Health Care, London, Ontario, Canada; the Hospital for Special Surgery, New York, New York, USA; the Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; the University of Toronto, Toronto; Southlake Regional Health Centre, Newmarket, Ontario; the Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke, Sherbrooke, Quebec; the Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; McMaster University, Hamilton, Ontario; and Western University, London, Ontario, Canada.
Source
J Rheumatol. 2013 Nov;40(11):1823-30
Date
Nov-2013
Language
English
Publication Type
Article
Keywords
Adult
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Canada
Disease Progression
Drug Therapy, Combination
Female
Humans
Male
Methotrexate - therapeutic use
Middle Aged
Practice Guidelines as Topic
Remission Induction - methods
Severity of Illness Index
Standard of Care
Treatment Outcome
Abstract
To determine site variation by comparing outcomes across sites in an early rheumatoid arthritis cohort.
Sites from the Canadian Early Arthritis Cohort database with at least 40 patients were studied. Comparisons were made among sites in change in 28-joint Disease Activity Score (DAS28), proportion of patients in DAS28 remission, and treatment strategies.
The study included 1138 baseline patients at 8 sites, with baseline (SD) age 52 years (16.9); 72% women; 23% erosions; 54% ever smokers; 51% rheumatoid factor-positive; 37% anticitrullinated protein antibody-positive; disease duration 187 (203) days; DAS28 4.5 (1.4). Site had an effect on outcomes when adjusting for confounders. At 6 and 12 months, sites B and H, the 2 largest sites, had the best changes in DAS28 (-1.82 and -2.09, respectively, at 6 mos, and -2.27 for both at 12 mos; p
PubMed ID
24037554 View in PubMed
Less detail

Early management of newly diagnosed rheumatoid arthritis by Canadian rheumatologists: a national, multicenter, retrospective cohort.

https://arctichealth.org/en/permalink/ahliterature131696
Source
J Rheumatol. 2011 Nov;38(11):2342-5
Publication Type
Article
Date
Nov-2011
Author
Ruben Tavares
Janet E Pope
Jean-Luc Tremblay
Carter Thorne
Vivian P Bykerk
Juris Lazovskis
Kenneth L N Blocka
Mary J Bell
Diane Lacaille
Carol A Hitchon
Avril A Fitzgerald
Wesley K Fidler
Arthur A M Bookman
James M Henderson
Dianne P Mosher
Dalton E Sholter
Majed Khraishi
Boulos Haraoui
Hong Chen
Xiuying Li
Andreas Laupacis
Gilles Boire
George Tomlinson
Claire Bombardier
Author Affiliation
McMaster University, Hamilton, Canada. ruben.tavares@sympatico.ca
Source
J Rheumatol. 2011 Nov;38(11):2342-5
Date
Nov-2011
Language
English
Publication Type
Article
Keywords
Adult
Antirheumatic Agents - therapeutic use
Canada - epidemiology
Cohort Studies
Disability Evaluation
Disease Management
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Outcome Assessment (Health Care)
Physician's Practice Patterns
Retrospective Studies
Rheumatic Fever - diagnosis - drug therapy - epidemiology
Severity of Illness Index
Treatment Outcome
Abstract
To describe early rheumatologic management for newly diagnosed rheumatoid arthritis (RA) in Canada.
A retrospective cohort of 339 randomly selected patients with RA diagnosed from 2001-2003 from 18 rheumatology practices was audited between 2005-2007.
The most frequent initial disease-modifying antirheumatic drugs (DMARD) included hydroxychloroquine (55.5%) and methotrexate (40.1%). Initial therapy with multiple DMARD (15.6%) or single DMARD and corticosteroid combinations (30.7%) was infrequent. Formal assessment measures were noted infrequently, including the Health Assessment Questionnaire (34.6%) and Disease Activity Score for 28 joints (8.9%).
Initial pharmacotherapy is consistent with guidelines from the period. The infrequent reporting of multiple DMARD combinations and formal assessment measures has implications for current clinical management and warrants contemporary reassessment.
Notes
Comment In: J Rheumatol. 2011 Nov;38(11):2287-922045932
PubMed ID
21885485 View in PubMed
Less detail

Incidence and predictors of secondary fibromyalgia in an early arthritis cohort.

https://arctichealth.org/en/permalink/ahliterature122649
Source
Ann Rheum Dis. 2013 Jun;72(6):949-54
Publication Type
Article
Date
Jun-2013
Author
Yvonne C Lee
Bing Lu
Gilles Boire
Boulos Paul Haraoui
Carol A Hitchon
Janet E Pope
J Carter Thorne
Edward Clark Keystone
Daniel H Solomon
Vivian P Bykerk
Author Affiliation
Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. ylee9@partners.org
Source
Ann Rheum Dis. 2013 Jun;72(6):949-54
Date
Jun-2013
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antibodies - immunology
Arthritis - epidemiology
Arthritis, Rheumatoid - epidemiology
Canada - epidemiology
Cohort Studies
Female
Fibromyalgia - epidemiology
Humans
Incidence
Male
Mental Disorders - epidemiology
Middle Aged
Pain Measurement
Peptides, Cyclic - immunology
Proportional Hazards Models
Prospective Studies
Risk factors
Severity of Illness Index
Abstract
Secondary fibromyalgia (FM) is common among patients with inflammatory arthritis, but little is known about its incidence and the factors leading to its development. The authors examined the incidence of secondary FM in an early inflammatory arthritis cohort, and assessed the association between pain, inflammation, psychosocial variables and the clinical diagnosis of FM.
Data from 1487 patients in the Canadian Early Arthritis Cohort, a prospective, observational Canadian cohort of early inflammatory arthritis patients were analysed. Diagnoses of FM were determined by rheumatologists. Incidence rates were calculated, and Cox regression models were used to determine HRs for FM risk.
The cumulative incidence rate was 6.77 (95% CI 5.19 to 8.64) per 100 person-years during the first 12 months after inflammatory arthritis diagnosis, and decreased to 3.58 (95% CI 1.86 to 6.17) per 100 person-years 12-24 months after arthritis diagnosis. Pain severity (HR 2.01, 95% CI 1.17 to 3.46) and poor mental health (HR 1.99, 95% CI 1.09 to 3.62) predicted FM risk. Citrullinated peptide positivity (HR 0.48, 95% CI 0.26 to 0.88) was associated with decreased FM risk. Serum inflammatory markers and swollen joint count were not significantly associated with FM risk.
The incidence of FM was from 3.58 to 6.77 cases per 100 person-years, and was highest during the first 12 months after diagnosis of inflammatory arthritis. Although inflammation was not associated with the clinical diagnosis of FM, pain severity and poor mental health were associated with the clinical diagnosis of FM. Seropositivity was inversely associated with the clinical diagnosis of FM.
Notes
Cites: Arthritis Rheum. 2005 Dec;52(12):3685-9216329076
Cites: Semin Arthritis Rheum. 2008 Oct;38(2):101-918221987
Cites: J Rheumatol. 2007 Apr;34(4):810-717299839
Cites: Rheumatology (Oxford). 2007 Jun;46(6):1009-1417401133
Cites: Clin Exp Rheumatol. 2007 Mar-Apr;25(2):225-3017543146
Cites: J Rheumatol. 2007 Jun;34(6):1415-2517552068
Cites: J Rheumatol. 2007 Dec;34(12):2382-717985407
Cites: Arthritis Rheum. 2009 Jun 15;61(6):794-80019479706
Cites: Arthritis Res Ther. 2009;11(3):R6119413909
Cites: Glia. 2009 Nov 1;57(14):1469-7919306358
Cites: Arthritis Res Ther. 2009;11(5):R16019874580
Cites: Rheumatology (Oxford). 2010 May;49(5):924-820100795
Cites: Semin Arthritis Rheum. 2010 Jun;39(6):448-5319250656
Cites: Semin Arthritis Rheum. 2010 Aug;40(1):15-3119217649
Cites: Ann Rheum Dis. 2010 Sep;69(9):1580-820699241
Cites: J Vasc Interv Radiol. 2010 Sep;21(9):1405-920800779
Cites: Arthritis Care Res (Hoboken). 2010 Oct;62(10):1370-620506177
Cites: J Rheumatol. 2010 Nov;37(11):2221-520716658
Cites: Pain Med. 2010 Sep;11(9):1391-40020735749
Cites: J Pain. 2010 Dec;11(12):1320-820488762
Cites: Pain. 2011 Feb;152(2):291-920961687
Cites: Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3731-621245297
Cites: Ann Rheum Dis. 2011 Jun;70(6):935-4221540201
Cites: J Rheumatol. 2011 Jun;38(6):1113-2221285161
Cites: Am J Epidemiol. 2011 Aug 1;174(3):267-7321633119
Cites: J Rheumatol. 2011 Aug;38(8):1546-5121632678
Cites: J Rheumatol. 2011 Oct;38(10):2238-4621765102
Cites: Arthritis Res Ther. 2011;13(2):21121542893
Cites: Best Pract Res Clin Rheumatol. 2011 Apr;25(2):165-7122094193
Cites: Semin Arthritis Rheum. 2011 Dec;41(3):319-3421665248
Cites: J Rheumatol. 2012 Jan;39(1):22-722002014
Cites: Arthritis Rheum. 2012 Jan;64(1):281-422081440
Cites: J Rheumatol. 1999 Nov;26(11):2458-6710555910
Cites: Pain. 2000 Apr;85(3):483-9110781923
Cites: Eur J Pain. 2002;6(2):161-7611900476
Cites: Pain. 2002 Sep;99(1-2):49-5912237183
Cites: Pain. 2003 Mar;102(1-2):87-9512620600
Cites: Lupus. 2003;12(4):274-912729050
Cites: Best Pract Res Clin Rheumatol. 2003 Aug;17(4):685-70112849719
Cites: J Rheumatol. 2004 Apr;31(4):695-70015088293
Cites: Clin Rheumatol. 1989 Dec;8(4):467-742612115
Cites: J Rheumatol. 1992 Jun;19(6):851-51404120
Cites: Med Care. 1996 Mar;34(3):220-338628042
Cites: J Rheumatol. 1999 Jul;26(7):1570-610405947
Cites: Arthritis Rheum. 2007 Dec;56(12):4015-2318050216
Cites: J Neurosci. 2008 May 14;28(20):5189-9418480275
Cites: J Pain. 2006 Sep;7(9):626-3416942948
PubMed ID
22791744 View in PubMed
Less detail

Increasing treatment in early rheumatoid arthritis is not determined by the disease activity score but by physician global assessment: results from the CATCH study.

https://arctichealth.org/en/permalink/ahliterature121074
Source
J Rheumatol. 2012 Nov;39(11):2081-7
Publication Type
Article
Date
Nov-2012
Author
Lonnie Pyne
Vivian P Bykerk
Gilles Boire
Boulos Haraoui
Carol Hitchon
J Carter Thorne
Edward C Keystone
Janet E Pope
Author Affiliation
Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.
Source
J Rheumatol. 2012 Nov;39(11):2081-7
Date
Nov-2012
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Canada
Cohort Studies
Decision Making
Disability Evaluation
Dose-Response Relationship, Drug
Female
Humans
Male
Middle Aged
Physicians
Prospective Studies
Regression Analysis
Severity of Illness Index
Abstract
To determine the factors most strongly associated with an increase in therapy of early rheumatoid arthritis (ERA).
Data from the Canadian Early Arthritis Cohort (CATCH) were included if the patient had = 2 visits and baseline and 6 months data. A regression analysis was done to determine factors associated with treatment intensification.
Of 1145 patients with ERA, 790 met inclusion criteria; mean age was 53.4 years (SD 14.7), mean disease duration 6.1 months (SD 2.8), 75% were female, baseline Disease Activity Score-28 (DAS28) was 4.7 (SD 1.8) and 2.9 (SD 1.8) at 6 months for included patients. Univariate factors for intensifying treatment were physician global assessment (MDGA; OR 7.8 and OR 7.4 at 3 and 6 months, respectively, p
Notes
Comment In: J Rheumatol. 2012 Nov;39(11):2064-523118278
PubMed ID
22942265 View in PubMed
Less detail

Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort.

https://arctichealth.org/en/permalink/ahliterature106116
Source
Rheumatology (Oxford). 2014 Mar;53(3):482-90
Publication Type
Article
Date
Mar-2014
Author
Tommy Choy
Vivian P Bykerk
Gilles Boire
Boulos P Haraoui
Carol Hitchon
Carter Thorne
Edward C Keystone
Janet E Pope
Author Affiliation
Department of Rheumatology, St Joseph's Health Care, 268 Grosvenor St., London, ON, N6A 4V2, Canada. janet.pope@sjhc.london.on.ca.
Source
Rheumatology (Oxford). 2014 Mar;53(3):482-90
Date
Mar-2014
Language
English
Publication Type
Article
Keywords
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - blood - diagnosis - drug therapy
Biological Products - therapeutic use
Blood Sedimentation
C-Reactive Protein - metabolism
Cohort Studies
Female
Follow-Up Studies
Glucocorticoids - therapeutic use
Humans
Male
Middle Aged
Ontario
Pain Measurement - methods
Patient Outcome Assessment
Predictive value of tests
Prognosis
Prospective Studies
Regression Analysis
Remission Induction
Retrospective Studies
Treatment Outcome
Abstract
The objective of this study was to determine predictors of 1-year remission in early RA (ERA) using baseline and 3-month data.
The Canadian Early Arthritis Cohort (CATCH) patients were included if baseline, 3- and 12-month data were available. Regression analyses for four different definitions of remission at 12 months were done to determine baseline and 3-month predictors of remission.
Five hundred and sixty-two patients had complete data at 12 months (mean age 53.4 years, disease duration 6.2 years, 73% female). The factors at baseline associated with all four remission outcomes at 12 months were age, gender, income, education, tender joint count (TJC), patient global assessment (PtGA), HAQ and pain. Baseline ESR was associated with the 28-joint DAS (DAS28) remission only. At 3 months, all four remission definitions were associated with TJC, swollen joint count, physician global assessment (PGA), PtGA, HAQ, pain, ESR and CRP in univariate analyses. In the regression model, variables associated with Simple Disease Activity Index remission were PGA [odds ratio (OR) 0.77, P
PubMed ID
24241035 View in PubMed
Less detail

11 records – page 1 of 2.